Exploratory clinical trials with dendritic cell vaccines using a small cocktail of short peptide neoepitopes have shown that neoepitope-specific CD8+ T cells can be induced in humans.11 However, induction alone is not sufficient for cancer therapy since, in addition, those epitopes need to be displayed in sufficient quantity in the context of the appropriate MHC-I of the tumor target. Here, CD8A is linked to neoplasm.